644 related articles for article (PubMed ID: 26346135)
61. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
[TBL] [Abstract][Full Text] [Related]
62. The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
Macfarlane R; Heng DY; Xie W; Knox JJ; McDermott DF; Rini BI; Kollmannsberger C; Choueiri TK
Cancer; 2012 Jan; 118(2):365-70. PubMed ID: 21717427
[TBL] [Abstract][Full Text] [Related]
63. Comparison of Tyrosine Kinase Inhibitor
Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
[TBL] [Abstract][Full Text] [Related]
64. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
Al-Marrawi MY; Rini BI; Harshman LC; Bjarnason G; Wood L; Vaishampayan U; MacKenzie M; Knox JJ; Agarwal N; Al-Harbi H; Kollmannsberger C; Tan MH; Rha SY; Donskov FN; North S; Choueiri TK; Heng DY;
Target Oncol; 2013 Sep; 8(3):203-209. PubMed ID: 23300029
[TBL] [Abstract][Full Text] [Related]
65. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
66. Protein kinase inhibitors in renal cell carcinoma.
Daste A; Grellety T; Gross-Goupil M; Ravaud A
Expert Opin Pharmacother; 2014 Feb; 15(3):337-51. PubMed ID: 24328606
[TBL] [Abstract][Full Text] [Related]
67. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
68. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
Kruck S; Bedke J; Kuczyk MA; Merseburger AS
Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
[TBL] [Abstract][Full Text] [Related]
69. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Abbas M; Steffens S; Bellut M; Becker JU; Großhennig A; Eggers H; Wegener G; Kuczyk MA; Kreipe HH; Grünwald V; Schrader AJ; Ivanyi P
Med Oncol; 2016 Jun; 33(6):59. PubMed ID: 27165272
[TBL] [Abstract][Full Text] [Related]
70. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
Sadeghi S; Albiges L; Wood LS; Black SL; Gilligan TD; Dreicer R; Garcia JA; Escudier BJ; Rini BI
Cancer; 2012 Jul; 118(13):3277-82. PubMed ID: 22139966
[TBL] [Abstract][Full Text] [Related]
71. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
72. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
Ko JJ; Choueiri TK; Rini BI; Lee JL; Kroeger N; Srinivas S; Harshman LC; Knox JJ; Bjarnason GA; MacKenzie MJ; Wood L; Vaishampayan UN; Agarwal N; Pal SK; Tan MH; Rha SY; Yuasa T; Donskov F; Bamias A; Heng DY
Br J Cancer; 2014 Apr; 110(8):1917-22. PubMed ID: 24691425
[TBL] [Abstract][Full Text] [Related]
73. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
[TBL] [Abstract][Full Text] [Related]
74. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
75. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
Liontos M; Trigka EA; Korkolopoulou P; Tzannis K; Lainakis G; Koutsoukos K; Kostouros E; Lykka M; Papandreou CN; Karavasilis V; Christodoulou C; Papatsoris A; Skolarikos A; Varkarakis I; Adamakis I; Alamanis C; Stravodimos K; Mitropoulos D; Deliveliotis C; Constantinidis CA; Saetta A; Patsouris E; Dimopoulos MΑ; Bamias A
World J Urol; 2017 Mar; 35(3):411-419. PubMed ID: 27395374
[TBL] [Abstract][Full Text] [Related]
76. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
77. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
Vaishampayan U; Schöffski P; Ravaud A; Borel C; Peguero J; Chaves J; Morris JC; Kotecki N; Smakal M; Zhou D; Guenther S; Bajars M; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):275. PubMed ID: 31651359
[TBL] [Abstract][Full Text] [Related]
78. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
[TBL] [Abstract][Full Text] [Related]
79. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
Stitzlein L; Rao P; Dudley R
Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
[TBL] [Abstract][Full Text] [Related]
80. PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy.
Jiang W; Wang D; Liu X; Zheng W; Wen L; Shi H; Zhang H; Zhou A; Li C; Ma J; Zheng S; Shou J
Urol Oncol; 2021 Jan; 39(1):78.e9-78.e16. PubMed ID: 32988712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
